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andomized controlled trials (RCTs) have
become a cornerstone of evidence-based medicine, and
therefore have an important impact on clinical decision-
making and clinical practice. The clinical trial can be a
much more precise and accurate assessment of thera-
peutic potential than the anecdotal report or uncon-
trolled case series. However, clinical trials have impor-
tant limitations in terms of feasibility and generalizability
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State-of-the art clinical trial design and methodology are enormously important for the advancement of the field. In con-
trast, the critical relevance of trial conduct and implementation have only more recently been the focus of discussion and
research. Although randomized controlled trials are generally considered the gold standard for the assessment of phar-
macologic and nonpharmacologic interventions in medicine, trials are vulnerable to complications and influences that
can seriously compromise their success. Like interventions, trial design and conduct are also contextual. They need to
be individualized and adapted to a number of relevant variables, such as setting, population, illness phase, interventions,
patient and rater expectations and biases, and the overall aims of the investigation. While this means that there is no
unified approach possible, certain general principles and guidelines require careful consideration. Knowledge of basic
solutions and alternatives, and the recognition of the complex challenges that need to be addressed proactively can help
to minimize unwanted outcomes, including trial failure and uninformative or falsely negative outcomes. Moreover, novel
design alternatives need to be explored that target sample enrichment according to the study question and enhance-
ment of precision in the measurement of relevant outcomes. We propose two novel design strategies that take advan-
tage of the recently validated early antipsychotic response paradigm (that has also been observed with antidepressants
and mood stabilizers). In the “early responder randomized discontinuation design” all patients are assigned to the active
drug, and only those who had at least a minimal response at 2 weeks are enrolled in a double-blind, placebo-controlled
discontinuation trial, enriching the placebo controlled trial portion with true drug responders. In the mirror image “early
nonresponder randomized dose increase or augmentation design,” early nonresponders at 2 weeks are assigned to stay-
ing on the medication or going either to a higher dose or an augmentation agent. It is hoped that through increased
attention to the issues raised in this article and further refinement of trial methodology and conduct, the field will make
much needed additional progress in the prevention and treatment of schizophrenia.   
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PAGES_12_AG_1003_BA.qxd:DCNS#49  31/05/11  0:16  Page 155and can also fail or prove to be erroneous in their con-
clusions. The process of patient selection in clinical tri-
als further highlights the strengths and weaknesses of
the current nosology, and the prevalence of comorbid
conditions and other factors can also influence treatment
response. Moreover, the clinical trial serves to highlight
the ethical and scientific tension between striving for the
common good and the treatment of the individual per-
son. When and to what extent the use of placebos is
appropriate when proven effective treatments are avail-
able is an important and complex issue about which rea-
sonable people may disagree. In order for RCTs to serve
the common good in an optimal fashion, clinicians,
health care policy makers and other individuals with a
stake in influencing and evaluating clinical care must be
informed consumers of clinical trial data. Similarly, for
clinical trials to be informative, those involved must
carefully consider the opportunities and challenges of
trial design, methodology, conduct, implementation, and
interpretation.
In designing and conducting clinical trials, there is a con-
stant tension between the “perfect” and the “feasible,”
the desirable and doable, and between striving for sci-
entific excellence and clinical impact. This dichotomy
needs to be resolved proactively, consciously realizing
and weighing the cost and benefit of each decision
aimed at resolving this unavoidable conflict. It is in that
spirit that we provide the following overview of con-
trolled clinical trials in schizophrenia. We will first dis-
cuss the changing clinical and scientific context in which
RCTs are taking place, followed by a discussion of spe-
cific trial components and their importance.
Historical developments
The somewhat serendipitous observation that chlorpro-
mazine had a pronounced “calming” activity that
extended to benefits for psychotic signs and symptoms
was one of the great advances in 20th-century medicine.
This effect was observed without the benefit of an RCT.
Chlorpromazine was subsequently approved by the
Food and Drug Administration in 1954, and by 1964,
approximately 50 million people around the world had
been treated with this medication.
In 1949, the World Health Organization published the
sixth revision of the International Statistical Classification
of Diseases (ICD), which for the first time included a sec-
tion on mental disorders.
1The first official Diagnostic and
Statistical Manual of Mental Disorders (DSM) was pub-
lished in 1952 by the American Psychiatric Association.
2
Diagnostic criteria were not really specified for discrete
disorders until the third edition of DSM (III),
3 which
attempted to improve the validity and reliability of psy-
chiatric diagnosis. This, in turn, had enormous implica-
tions for clinical practice, clinical research and drug
development.
In 1969, Klein and Davis published a seminal work enti-
tled  Diagnosis and Drug Treatment of Psychiatric
Disorders.
4 In the introduction, they wrote, 
“We may be fortunate to be entering a period in which
rational comparative study will become standard for ther-
apeutic decision. Although clinical hunches and results of
clinical experience are important factors in the determina-
tion of proper treatment, the findings of research studies,
particularly those which are done with controlled double-
blind technique, provide the behavioral scientific data for
informed decision.” 
By 1969, Klein and Davis identified 126 controlled stud-
ies comparing antipsychotic drugs and placebo in which
the medications were found to be more effective and 26
comparisons in which they were not.
4They also examined
the role of dose adequacy and found that most of those
studies that found chlorpromazine to be ineffective used
very small doses, and all 23 studies that employed doses
over 500 mg/day were positive. Similarly, in all studies,
which were judged to be methodologically rigorous, the
phenothiazine derivatives (and reserpine) were shown to
be more effective than the control conditions. These data
led to an enormous shift in clinical practice, with antipsy-
chotic drugs becoming the critical component in the
treatment of schizophrenia.
Treatment-refractory illness and clozapine
With the development and initial evaluation of clozap-
ine in Europe, early observations suggested a novel com-
pound had been developed with a qualitatively different
clinical profile that included the relative absence of
drug-induced extrapyramidal effects and potentially
superior efficacy in patients who had failed other anti-
dopaminergic agents. However, a series of cases of
agranulocytosis
5 led to a delay in the further develop-
ment of clozapine in the US. Based on a large RCT with
prospective validation of treatment refractoriness
demonstrating clozapine’s superiority over chlorpro-
mazine in refractory schizophrenia,
6 the FDA approved
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tant patients in 1990. Since then, clozapine’s singular role
in treatment-refractory patients with schizophrenia has
been confirmed
7 and its role in the management of sui-
cidality has also been established.
8 Nevertheless, recent
meta-analyses
9 did not uniformly confirm clozapine’s
superiority over other antipsychotics in schizophrenia.
Again, several design issues need to be considered when
evaluating this inconsistency, including inappropriately
low doses of clozapine
9, as well as the lack of selection
for truly resistant patients.
Attention to first-episode schizophrenia
Beginning in the mid 1980s increased attention to first-
episode patients seemed warranted to evaluate treat-
ment outcomes that are unconfounded by the effects of
prior treatment, multiple relapses, and chronic illness.
11-13
Studies revealed cognitive and psychosocial deficits that
were present at illness onset,
14 a long duration of
untreated psychosis prior to first mental health contact,
15
increased sensitivity to medication side effects,
16 but also
a better treatment response compared with more chron-
ically ill patients.
17 Exploring biological heterogeneity
and treatment response at this phase has become an
important focus. In addition, as part of the move toward
the early treatment of schizophrenia, and the response
to new FDA incentives, the efficacy of antipsychotics has
also demonstrated in adolescents with schizophrenia.
18
In adolescents, appropriate selection criteria and trial
design considerations are also critical.
Comparative efficacy and effectiveness of
first-generation and second-generation
antipsychotics
With the introduction of second-generation antipsy-
chotics, there were observations of lower extrapyrami-
dal side-effect burden and tardive dyskinesia risk and
expectations of superior efficacy for positive, negative,
and cognitive symptoms.
19 Initial efficacy studies seemed
to confirm the superiority of second-generation antipsy-
chotics, but the comparator consisted predominantly of
haloperidol, used at moderate to high doses and often
without anticholinergic cotreatment, which made early
treatment discontinuation and secondary negative symp-
toms more likely in haloperidol treated patients. Since
then, a series of acute phase and longer-term studies
have been completed,
20-24 including large efficacy-effec-
tiveness hybrid trials that compared first- and second-
generation antipsychotics. These data have led to vary-
ing conclusions. Interpretations include that there is no
difference between first- and second-generation antipsy-
chotics, that second-generation antipsychotics are supe-
rior to first-generation antipsychotics, that some second–
generation antipsychotics are superior to either all or
some first-generation antipsychotics, in general, or in cer-
tain efficacy and/or side effect domains, or in patient
subgroups that are not yet easily identified prior to
choosing a specific agent. Since such a number of diver-
gent interpretations have been offered, this indicates
that blanket statements do not do justice to the complex
data base. Moreover, in comparative trials, design issues
are highly relevant to interpretation of the data,
25 includ-
ing sample size, choice of dose of the study drug and
active comparator, prior treatment, blinding, duration of
treatment, patient and rater expectations and biases,
choice of outcomes, handling of dropouts and interpre-
tation of the data, all of which we will discuss in detail
below.
Shifting adverse event focus to physical
health
Following the predominant use of second-generation
antipsychotics, there has been a shift in side effect con-
cerns from Parkinsonism and tardive dyskinesia, to phys-
ical health risks and outcomes that are associated with
decreased longevity.
26-30 Even more so than the study of
tardive dyskinesia, the study of adverse effect risks that
are either rare or distal outcomes that occur after many
years of illness and antipsychotic exposure pose formi-
dable challenges. This applies to study of sudden cardiac
death as a potential consequence or QTc prolongation
or other arrhythmogenic properties of antipsychotics,
31
as well as to diabetes and cardiovascular and cere-
brovascular morbidity and mortality. Since these out-
comes occur generally after many years or represent
premature onset of disorders that also occur in the gen-
eral population, RCTs might not be the best way to
assess the comparative safety of antipsychotics.
32 In fact,
RCTs have largely focused on the assessment of risk fac-
tors (such as weight gain, lipid and glucose abnormali-
ties) for cardiovascular and cerebrovascular illness,
rather than on the development of such illnesses them-
selves. An exception is the assessment of death and cere-
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elderly, which, by definition, is an enriched, high-risk
cohort. Even here, however, the increased risk with
antipsychotics was only uncovered after pooling all data
from placebo controlled RCTs in meta-analyses.
33These
examples highlight the fact that for some outcomes, such
as rare and temporally distal events, meta-analyses,
34
pharmacoepidemiologic studies,
31,35 and cohort studies
36
or registries are more useful than RCTs. This is true,
despite the considerable limitations of meta-analyses
and pharmacoepidemiologic studies and registries. Thus,
these methods are merely hypothesis-generating, requir-
ing follow-up with mechanistic studies and RCTs in
enriched samples that were informed by meta-analytic,
pharmacoepidemiologic, and registry data.
Raising the bar for outcomes
In addition to a broadened focus on physical health, out-
comes other than symptomatic improvement have
become standard in the field including more systematic
and operationalized approaches to measuring response,
remission and recovery,
37-40 subjective well-being and
quality of life,
41,42 cognition
43-45 and psychosocial/voca-
tional performance.
46-48These have become end points of
increasing importance in routine practice and in clinical
trials. However, focusing on such outcomes also requires
specific considerations, including treatment modalities,
trial duration, assessments, end points, etc.
Targeting individualized treatment
In addition to raising the bar for outcomes, the ways to
measure and predict them have also become topics of
increasing interest. Efforts at increasing the predictabil-
ity of outcomes for individual patients (ie, personalized
medicine) have included clinically driven nosological
and phenomenological approaches, but, so far, these
have not really succeeded.
49 Current approaches that do
not yet have consistent clinical applicability include the
use of genetics, neuroimaging, neurocognition, and
blood- or tissue-based biomarkers and sets of biomark-
ers, also called biosignatures.
50 Similarly, developments
are underway to define biomarkers as surrogate end
points in drug development.
51 To achieve personalized
psychiatric treatments, specific design considerations are
needed. These include ways of decreasing the hetero-
geneity of the study population and the parsing of clini-
cal and biological variables that are relevant for specific
mechanisms and treatment effects. In addition, relevant
treatment mediators and moderators can serve as selec-
tion criteria and randomization or stratification vari-
ables. However, obviously, these approaches will depend
on the identification of markers that predict treatment
outcome to specific interventions and that are not “just”
markers of general illness severity and responsiveness
(although even such general markers could, for example,
help to facilitate early identification of patients who
should have a trial of clozapine).
52,53 One such potentially
useful “biomarker” or endophenotype that we will dis-
cuss subsequently is the presence or absence of early
minimal clinical response, which might be useful to
enrich samples for specific studies.
Commercialization and globalization 
of clinical trials
Another historical element in any discussion of RCTs is
the “commercialization” and “globalization” of research.
In the early days of clinical trials in psychopharmacol-
ogy, there were a relatively small number of largely aca-
demic sites which participated in the design and conduct
of such investigations. The development of a specialized
clinical trials network was greatly facilitated by the
establishment of the “Early Clinical Drug Evaluation
Units” by the Psychopharmacology Research Branch at
NIMH. Over the last few decades, there has been an
enormous shift in the locus of clinical trials from acade-
mia to more commercial sites, from the US and Europe
to many other countries, and a much greater involve-
ment of a variety of vendors and middlemen in the man-
agement and conduct of such trials. The reasons for and
consequences of this shift are complex and varied, and a
detailed discussion is beyond the scope of this paper.
This phenomenon will be discussed subsequently in rela-
tion to patient recruitment as well as study implementa-
tion and management.
Designing RCTs in schizophrenia
The essential first step in designing any trial, however,
is to determine ‘what is the question?’ All too often
investigators attempt to address more than one ques-
tion in the same clinical trial. Although there is often an
opportunity to collect meaningful data on several pri-
mary and secondary outcome measures simultaneously,
State of the art
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in some cases (eg, the efficacy of a putative therapeutic
agent for cognition on negative symptoms or agitation),
a specific and distinct type of sample and trial design is
needed. Once the primary question is established,
patient selection, randomization strategy, treatment
selection and controls/comparator(s), trial duration,
assessment measures, power analysis, and statistical plan
will be the focus of attention. The degree to which
appropriate decisions are made regarding these issues
will be critical in the success of the trial. We will return
to these issues in the subsequent sections of this paper.
Types of trials
Like any other scientific method, RCTs have specific
strengths and weaknesses (Table I). These need to be
considered and adapted to the specific aim of the inves-
tigation. One important decision is the degree to which
real world characteristics of populations, treatments, and
procedures are systematically restricted and standard-
ized. There are a number of broad categories in which
RCTs can be placed. Efficacy studies involve clearly
defined and often narrow populations of patients who
can be studied with some frequency and intensity with a
variety of measures, which would not likely be used in
routine clinical practice. Primary outcomes of interest
ordinarily include symptom reduction on a validated and
reasonably comprehensive scale that is rarely used in
routine treatment. While this procedure increases the
chance of finding specific efficacy or tolerability signals,
the sample and settings in which this signal is detected
might become so restricted that as few as 10% to 20%
of individuals with a given diagnosis are enrolled,
54,55
affecting the generalizability of the findings.
Effectiveness trials, on the other hand, involve a broader
patient population intended to facilitate greater
(although still imperfect) generalizability of the trial
results to “real-world” patients and less intensive and
frequent assessments with more objective and easily
determined outcome measures, such as all-cause dis-
continuation, hospitalization, or death. Effectiveness
studies are more likely to include issues such as adher-
ence, tolerability, and quality of life as well as evaluation
of the overall impact of a specific treatment. Large “sim-
ple” trials or pragmatic/practical trials ideally should
include much larger numbers of patients than would be
feasible to include in an efficacy study; however, large,
multicenter, recruitment efforts can certainly result in
sizeable numbers of subjects participating in efficacy
studies as well. Other types of trials include crossover
and adaptive or sequential designs, which are described
in more detail below.
Patient characteristics and selection
Sponsors and funding agencies usually conceptualize
acute treatment as that involving recently relapsed or
exacerbated patients (often newly admitted to a hospi-
tal). However, some investigators include patients who
have been chronically symptomatic, but with a symptom
severity level great enough to qualify for the study. This
alternative approach can lead to the inclusion of patients
with varying degrees of potential drug responsiveness.
In addition, even if patients are recently relapsed and
admitted to hospital, if they have been treated for 2 or
more weeks prior to going into the study, their partial
treatment (or established poor response) might limit the
determination of the full therapeutic potential of the
treatments to which they are assigned. That patients
have already been partially treated does not necessarily
mean that a significant drug effect will not be evident,
but the magnitude and time course of that effect and,
ultimately, the statistical power can be affected.
Age is another important consideration not only
because of the relative prevalence of comorbid medical
conditions with increasing age, but also because of
potential differences in patterns of response depending
upon the phase of illness. Consideration should be given
to both age and duration of illness in selecting patient
populations for clinical trials. Response patterns, dosage
requirements, and vulnerability to side effects are, for
example, quite different in first-episode vs more chron-
ically ill patients.
16,56
The duration of the current episode is a factor which has
been given insufficient attention in most clinical trials.
Recent work
57-61 has suggested that a substantial propor-
tion of the response to antipsychotic agents (at least for
“positive” symptoms) is likely to occur in the first 1 or 2
weeks of treatment. Therefore, as suggested previously,
if a patient has been treated for more than a week or 2
prior to entering the trial it is likely that considerable
drug response has already taken place. In some cases,
patients need to be at least partially treated before they
will be available to participate in a clinical trial, but doc-
umentation of length and type of prior treatment in the
current episode would help in interpreting results, par-
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Selected trial characteristics Strengths Weaknesses
Restricted inclusion criteria High internal validity Limited external validity/generalizability
Specific signal detection capacity in carefully selected  Difficulty assessing optimal dosing in unrestricted, more
target population heterogeneous or seriously ill sample
Usable for regulatory and registration purposes Decreased knowledge about response and side effect 
patterns in patients with comorbid psychiatric and/or 
medical conditions
Slow enrolment
Randomization Controlling for measured and, especially, unmeasured  Selection bias towards a less generalizable sample
group differences (less severely ill, more chronically ill patients; patients 
with prior stabilization or treatment phase)
Challenges associated with placebo controls,  Selection bias towards a less generalizable sample (less
maintaining blind in the face of specific adverse effects severely ill, more chronically ill patients; patients with 
prior stabilization or treatment phase)
Small-to-medium sized More homogeneous and carefully characterized samples Reduced generalizability
samples
Need for multiple research-oriented sites
Low signal detection for rare outcomes
Specialized settings Greater potential for careful selection and  Reduced generalizability
diagnostic/assessment 
More control over study procedures  Fewer potential sites
Greater comfort using placebo controls Greater likelihood of professional patients
Study conduct by well-trained personnel with allocated  Lower enrolment rates
research time 
Potentially less access to patients of interest (eg, 
acute exacerbations, drug-naïve)
Frequent visits Controlled treatment and assessment Reduced generalizability
Better assurance of patient safety Reduced enrolment 
More systematic quantitative assessments for  Increased burden and dropouts
therapeutic and adverse effects
Increased opportunity to facilitate/monitor adherence Frequent quantitative assessments not done in 
clinical practice
Greater ability to use informative laboratory tests
Better assessment of use of ancillary services or use of  Potential influence on specific, investigated effect by 
other medications increased contact
Comprehensive assessments Specific assessment of measurable outcomes (including  Primary/secondary outcomes rarely assessed in
safety and tolerability) using validated and reliable  clinical practice.
scales administered by well-trained personnel
Usable for regulatory and registration purposes Patient/caregiver rated outcomes, quality of life and 
functional capacity rarely assessed in clinical practice
Use of quantitative measures unlikely in clinical 
practice and clinicians not trained in their use
Need for careful training and ongoing supervision 
of raters
Increased burden and dropouts
Cost Usable for regulatory and registration purposes Increased per-patient costs
Usable for potential marketing
Table I. Randomized controlled trials: strengths and weaknesses.
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patients who have been chronically symptomatic and
have not had a recent exacerbation.
In this context, it is also important to consider the pres-
ence and potential duration of a washout period (which
may or may not be placebo-controlled, double- or sin-
gle-blind). In some cases, investigators might use this not
only to eliminate the adverse effects of other drugs, but
also to see the severity of untreated symptoms. It is
important from an ethical and scientific standpoint that
it is clear what the expectations from a washout period
really are. In addition, as we will discuss subsequently,
we do not have good data on the time course of poten-
tial symptom worsening among those patients who are
partially treated and who then have their medication dis-
continued. There are a number of practical constraints
on drug washout, which include increased length of trial
duration, hospital stay, staff requirements, etc. Without
an adequate washout, however, it can be difficult to
establish a true baseline for both psychopathology and
adverse effects. In addition, there might be withdrawal
effects from the prior agent,
62 which could complicate
interpretation of data on a newly instituted medication.
The use of a concurrent placebo group can help to mit-
igate some of these concerns, and this is one important
argument for the use of placebos in such trials.
Documentation of response to previous treatment in
prior episodes can be difficult to obtain on a retrospec-
tive basis; however, this can also be important in elimi-
nating potential poor or partial responders. Many cur-
rent trials stipulate this exclusion criterion, but little is
done to validate these assumptions and, given the pres-
sure to enter subjects, there is likely some slippage in this
domain.
There is increasing focus on studying patients who have
poor or partially responsive symptoms in specific
domains of psychopathology, such as negative, positive,
or cognitive dysfunction. The selection of such patients
is also a challenge, as the retrospective documentation
of the stability and persistence of symptoms despite ade-
quate trials (and with some evidence of treatment adher-
ence) can also be difficult and requires special effort in
both the design and execution of appropriate RCTs. In
addition, cross-sectionally, negative symptoms can be dif-
ficult to differentiate from drug-induced Parkinsonism,
depression, demoralization or guardedness. Negative
symptoms may also be a secondary (possibly adaptive)
response to positive symptoms. Therefore, a longitudi-
nal, prospective approach might be necessary to identify
eligible patients for such studies.
The presence of comorbid substance abuse and/or other
psychiatric conditions is often an exclusion criterion in
efficacy trials, but not in practical trials. Suicidality has
usually been an exclusion criterion for clinical trials, but
it has been shown to be a feasible target for RCTs it its
own right with appropriate safeguards.
63The presence of
comorbid medical conditions or abnormal laboratory
tests has also become an increasing concern given the
potentially high rates of metabolic syndrome, smoking,
etc. among people with schizophrenia.
Randomization strategies
Most RCTs use even randomization strategies, which
assign equal numbers of patients to each treatment arm.
This makes sense since the smallest arm will determine
the statistical power involved in the comparison between
treatments. However, there are some situations where
equal randomization might not be appropriate.
Equipoise randomization
64 has been used in some trials
and can provide patient and physician input into the
potential options involved in the treatment assignment
without doing away with randomization altogether.
Adaptive design is another strategy which entails the use
of data already collected to influence subsequent ran-
domization of treatment groups.
65 This can be particu-
larly useful in studies involving dose-finding; however, it
can also lead to premature closure of a study arm or an
entire study based on relatively small amounts of data.
Sequential design allows pairing of individuals who are
assigned to alternate treatments with the results of each
subsequent pair contributing to an ongoing analysis of
the odds of reaching a significant effect or not.
65This can
provide statistical significance with a small number of
patients if the treatment effect is substantial, or it can
provide an initial confirmation of the null hypothesis.
Such a design has rarely been used in RCTs in schizo-
phrenia,
66 but should be considered.
Stratified randomization is an important tool to ensure
that the treatment arms are balanced on a small number
of potentially important mediating or moderating vari-
ables. The number of such variables will be determined
by the overall sample size. Crossover studies are also
conducted in some situations, but given potential med-
ication carryover effects and uncertainty as to how vul-
nerable patients are to returning to their baseline state
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tive in psychiatry than they might be in some medical
conditions. So-called “switch” studies are often done in
psychiatry, but unless there is a control group they can-
not be considered RCTs. Switch studies are obviously
much more informative if patients are randomized to be
switched or to stay on the original treatment, in a dou-
ble-blind fashion.
Blinding
While blinding/masking is an important feature to min-
imize expectation biases, blinding patients and providers
to the treatment does not match clinical practice.
Moreover, this feature can reduce enrolment and reten-
tion and blinding can be undone by known or expected
adverse effects, pill characteristics (overcoating, taste) or
administrative/procedural issues, such as different treat-
ment providers for different interventions or availabil-
ity of laboratory test results that are differentially
affected by treatments. A compromise that is sometimes
used is  randomized, open treatment with utilization of
masked raters, but care needs to be taken to maintain
the masking.
Treatment selection
The choice of treatment and control(s) will, of course, be
heavily influenced by the basic question that the RCT is
intended to address. The choice of active control and the
target dose(s) of both the investigational medicine and
the control agent are important. Estimates of therapeu-
tic equivalence and comparative adverse effect profiles
are affected by these choices. If a dose is too low, efficacy
may be suboptimal, but if a dose is too high it might
inflate the incidence of adverse effects. Titration sched-
ules can also be important for some drugs as well as
bioavailability issues related to food ingestion, or meta-
bolic issues related to smoking, body weight, concomi-
tant medications, etc. The side effect profiles of the
experimental drug and comparator can also lead to func-
tional unblinding and should be considered from that
standpoint as well, or methods can be used to reduce the
likelihood of such effects by using an ineffective low
dose of the experimental drug as a pseudoplacebo, or
separating the ratings of efficacy from those of tolera-
bility, or using centralized raters who do not follow the
same patient through a trial.
An important and potentially difficult issue is the extent
to which and what kind of “rescue” medication should
be made available to those individuals who might oth-
erwise drop out of the trial due to lack of efficacy and
need for further treatment. This possibility can compli-
cate the assessment of the therapeutic agent. However,
in some settings it is difficult to conduct a controlled trial
without such a provision. As will be discussed subse-
quently, the possibility of treating all patients initially
with active agents, identifying those with a clear early
response and then enrolling only the latter subjects in
a double-blind, placebo controlled discontinuation study
could be a powerful strategy to detect a true drug effect
while exposing a minimal number of patients to placebo.
Comedications
The permission, timing, and dosing of comedications also
requires consideration. Comedications are useful to limit
adverse effect burden and dropouts, but can obscure
true treatment effects. Moreover, differential washout of
comedications in treatment groups prior to randomiza-
tion can create confounds, whereas overly limited use of
comedications might limit the feasibility of the trial and
not match clinical reality.
Placebo controls
Recent discussion regarding placebo controlled clinical
trials in schizophrenia has largely focused on ethical
issues. The World Medical Association´s Declaration of
Helsinki
67 stipulates that “The use of placebo is accept-
able in studies where no current proven intervention
exists; or where for compelling and scientifically sound
methodological reasons the use of placebo is necessary
to determine efficacy or safety of an intervention and
the patients who receive placebo or no treatment will
not be subject to any risk of serious or irreversible harm.
Extreme care must be taken to avoid abuse of this
option.” Many investigators and, very importantly, reg-
ulatory agencies, such as the Food and Drug
Administration in the US and the European Medicines
Agency, have taken the position that a valid evaluation
of a treatment for schizophrenia (in terms of both effi-
cacy and safety) is not possible without a placebo-con-
trolled design, unless the goal is to demonstrate superi-
ority of the experimental agent over existing treatments.
As a result, every antipsychotic that has been approved
State of the art
162
PAGES_12_AG_1003_BA.qxd:DCNS#49  31/05/11  0:16  Page 162for the treatment of schizophrenia in either the US or
Europe in the past 20 years has been assessed for acute
efficacy in placebo-controlled clinical trials.
However, such designs have been challenged.
68-70 In addi-
tion, ethical committees in many settings are imple-
menting stricter standards, making it increasingly diffi-
cult to conduct placebo controlled clinical trials in
schizophrenia. Furthermore, high dropout rates have
been reported in clinical trials utilizing placebo con-
trols,
71 and there has also been a decrease in the drug
effect observed in clinical trials comparing both experi-
mental and approved antipsychotics with placebo.
72-74
There are a number of potential factors which contribute
to these findings ranging from protocol design to patient
selection and assessment procedures. Moreover, unex-
pectedly high placebo response is also seen in patients
enrolled in augmentation studies who were supposed to
have stable, unresponsive residual symptoms.
75 Taken
together, all of these factors underscore the importance
of carefully considering the benefits and risks of placebo
controlled trials, evaluating alternative strategies to
achieve needed goals in drug development and ensuring
that when placebos are involved that trials are imple-
mented and conducted in such a way as to not inflate or
exaggerate the placebo response. It is also important to
distinguish between different types of trials, since acute
treatment and maintenance treatment trials, or studies
of treatment resistant patients, etc. might provide vary-
ing challenges in this context.
Trial duration
Both feasibility and scientific considerations influence
the length of a trial. Though the full therapeutic benefit
of antipsychotics might not be seen for weeks or months,
the greatest proportion of response occurs within the
first few weeks,
57,58 although this pattern is somewhat
less clear for first-episode patients.
76,77 Improvement in
positive symptoms can even be seen in a matter of hours
or days.
78The potential use of placebo controls in short-
term, acute treatment trials argues for as short a dura-
tion as possible, in that those patients who are assigned
to placebo are more likely to experience further exac-
erbation or lack of response and, therefore, terminate
prematurely. Those patients who respond to placebo will
be more likely to remain in the study, thereby compli-
cating statistical analysis, diminishing the drug placebo
difference and reducing generalizability. In many stud-
ies, a significant drug effect can be seen after 1 or 2
weeks. However, if drugs with novel mechanisms are the
focus of investigation then assumptions about time
course of response might be less reliable. There is also a
subgroup of patients who are slower to respond and if
the ultimate goal is to compare the full therapeutic
potential of alternative treatments, then a longer trial
might be desirable. Issues related to trial duration in
maintenance of effect/relapse prevention studies will be
discussed subsequently.
Outcome and assessment measures
The selection of assessment measures and instruments
will be largely driven by the choice(s) of the primary
and secondary outcome measures as well as by feasi-
bility and rater/patient burden. Often, too many scales
are included in a clinical trial and some of the data are
never analyzed or published. Attention to scale valid-
ity and reliability is also important, and in regulatory
trials there is a particular emphasis on instruments,
which have been demonstrated on a broad scale to
have the desired characteristics. If a new scale is intro-
duced, it is often recommended to have an existing and
widely utilized scale for the same domain included as a
reference point. As there is increasing emphasis on
patient reported outcomes, however, there is also some
concern as to the validity of such measures for those
individuals who are lacking in insight or unable to reli-
ably evaluate their own subjective and/or functional
state. In the case of schizophrenia, informant informa-
tion can also be extremely valuable. Patient-reported
outcomes in some cases can be impeded by willful con-
cealment or distrust of the interviewer or interview sit-
uation. Clearly, as broader outcome assessments are
called for, measures of negative symptoms, cognitive
function, social and vocational performance/quality of
life, subjective well-being, family burden, etc should be
considered.
In contrast to some dimensions of psychopathology, the
longer time frame needed to assess the amelioration of
negative symptoms and cognitive dysfunction or
improvements in overall social and vocational adjust-
ment might require trials of much longer duration. This
is especially true if issues of persistence of effect are to
be clarified. Finally, it has been recognized that adverse
effects are not as carefully and comprehensively mea-
sured as efficacy measures.
79 This should also be reme-
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istered adverse effect check list to spontaneous report-
ing.
Quality of ratings and 
fidelity of assessments
In order to have a sufficient signal-to-noise detection
ratio for diagnostic, symptomatic and side effect assess-
ments, both the utilized tools and the raters performing
the interviews and ratings need to be highly reliable. In
fact, the intraclass correlation coefficient (ICC) between
ratings has a profound impact on sample size require-
ments. For example, an ICC of 0.9 requires 111 patients
compared with 200 patients if the ICC is 0.5 in order to
achieve the same statistical power.
80The way that raters
are trained and the manner in which reliability is estab-
lished varies. In fact, true interrater reliability is rarely
established in multicenter clinical trials. Specifically, hav-
ing prospective interviewers only rate videotaped assess-
ments performed by an expert does not establish the
kind of reliability that is necessary. Even high ICCs with
the expert rater do not in any way establish the ability of
the rater to elicit the same symptoms when conducting
an independent interview that he/she was able to rate
when being fed the patient responses in an idealized
training tape. Moreover, the method of rating even taped
interviews is not usually standardized, so that it is not
clear to what degree ratings occur completely indepen-
dent in the classroom. In addition, a sufficient number of
such assessments to establish statistical correlations is
rarely done. Furthermore, even if reliability was estab-
lished for both the interview and the rating, rater drift
needs to be countered by reassessing the reliability of the
ratings periodically throughout the trial, as well as train-
ing new raters when there is staff turnover. Other meth-
ods of increasing precision of ratings include comparing
similar outcome dimensions across different assessment
scales (ie, convergent validity) or checking rater-assessed
outcomes against patient reported outcomes or against
the evaluation of quality control by remote expert raters
(ie, external consistency). In case of obvious inconsisten-
cies, raters can then be approached and simply be given
feedback or they can be retrained. However, even though
expert raters can be used to check or adjudicate site
based ratings, they have to rely on the interviews that
may be less than optimal in obtaining a full clinical pic-
ture. Research has shown that many assessments were
deficient when site based interviews were audiotaped
and randomly assessed by expert raters.
81 Another
method, particularly for multisite studies that has shown
considerable promise to increase the reliability of ratings
and reduce placebo response,
82 includes the use of remote
centralized expert raters who perform the assessments
via live, two-way video. This method can be expensive
and poses some logistical challenges, but is in keeping
with the desire to centralize and standardize assessments
whenever possible, as has increasingly been done with
cardiology, pathology, radiology, and laboratory tests in
multicenter trials.
Relapse prevention
Relapse prevention in schizophrenia remains a major
public problem. However, the number of studies focus-
ing on relapse prevention/maintenance treatment is sub-
stantially smaller compared with acute phase trials.
83,84A
particular challenge in relapse prevention studies is the
definition of relapse, for which no universal criteria
exist.
83 Given ethical concerns about placebo-controlled
trials in relapse prevention, it has become customary to
utilize relapse criteria which do not require a full-blown
psychotic exacerbation, but rather rely on minimally
clinically significant early signs of relapse. Subsequently,
relapse rates might be higher than in studies conducted
previously, and there are a number of potential false pos-
itives.
The use of placebo controls in relapse prevention studies
is another source of controversy, and opinions of regula-
tory authorities also differ on this topic. Some would
argue that the demonstration of non-inferiority in com-
parison to a proven efficacious compound should be suf-
ficient. However, both dropout and response rates vary
whether an active or placebo control is used,
85 and relapse
rates vary enormously across trials. For example, a recent
trial comparing depot and oral medications reported
rehospitalization rates of 39% and 45%, respectively, in a
2-year study.
86 By contrast, other trials reported rehospi-
talization rates as low as 1.3% and 5.8% with depot and
oral medications, respectively, at 1 year,
87 and 9.3% and
15.2%, respectively, at 2 years.
88Therefore, it is difficult to
be certain if one is dealing with an ineffective medication
or with a patient population that is highly vulnerable to
relapse regardless of medication status.
Another important issue that needs to be considered
in the design of maintenance and relapse prevention
studies is the timing of the randomization. In most tri-
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phase and then continued into an extension mainte-
nance study. However, if patients are not rerandom-
ized after stabilization, the concern is that by includ-
ing randomly assigned, acutely exacerbated patients,
only those patients at risk for relapse who had
responded to and tolerated the specific acute treat-
ment participate in the maintenance portion of the
trial. This could lead to a selection bias for patients
who experienced less side effects or experienced more
improvement on the allocated medication. This con-
cern is particularly relevant when there are unequal
proportions of patients in each originally randomized
group that enter the maintenance and relapse preven-
tion phase of the study.
The degree to which patients entering the trial are sta-
ble and whether this is established retrospectively or
prospectively are other important considerations. As for
relapse, stability criteria and the required duration of sta-
bility or remission are insufficiently standardized.
Another important issue is the duration of the trial.
Since some long studies suggest different patterns of
relapse during the first and second years,
89,86,90 a duration
of 2 years or longer is ideal. But, of course, the longer the
duration, the higher the dropout rate might be. The
dropout rate varies from study to study, but some sur-
pass 50%. This issue is clearly more important in active-
active comparisons, as drug placebo differences can usu-
ally be seen in shorter time frames.
Finally, the determination of optimum dosing for main-
tenance/relapse prevention is a particular challenge,
given the unpredictable time course of relapse. Even
when patients are completely withdrawn from antipsy-
chotics when in a state of remission or stability, the
resulting relapse might not occur for weeks or months.
Therefore, if a flexible dose is used, it is difficult to deter-
mine whether or not a relapse is due to an ineffective
medication or if it is due to reducing the dose below an
efficacy threshold for that patient. Therefore, fixed-dose
studies are valuable in the maintenance phase to eval-
uate the dose response relationship, which might be
quite different from that observed in acute efficacy tri-
als where the goal is reducing acute and severe psy-
chopathology. Importantly, given high potential rates of
non adherence, the use of long-acting injectable med-
ications can be very valuable in this context to ensure
that nonadherence does not confound the interpretation
of dose-response relationships.
91-92
Statistical issues
Several issues of clinical trial design influence sample
size estimates and the power to detect a clinically mean-
ingful treatment effect, while maintaining a nominal
level of type I error. For example, multiple outcomes
can inflate type I error, and unreliable assessment
processes and imprecise measurements can introduces
biases and reduce statistical power.
93 In addition, miss-
ing data pose considerable challenges. It is increasingly
recognized that last-observation-carried-forward
(LOCF) analytic methods are problematic and that
mixed models repeated measures (MMRM) analyses
for continuous outcomes and Generalized Estimation
Equation (GEE) models are a superior way of handling
missing data. It took a while for regulatory agencies to
agree to this, but nowadays MMRM analyses are also
an acceptable analysis method for registration trials.
However, there are really no good solutions for dealing
with missing data that are almost never missing truly at
random. Even methods like MMRM and GEE that
adjust the analyses based on results from patients who
continued in the trial have their limitations, as their
validity is based on the assumption of ignorable attri-
tion,
94 highlighting the importance of minimizing
dropouts and missing data as much as possible. In fact,
dropout rates have become an increasing problem like
placebo response rates.
95 Thus, studies need to be
designed in ways to minimize dropout rates, for exam-
ple by not creating incentives for leaving the study early.
Incentives for patients may include a rollover in an
open long-term extension phase study where treatment
is free, while incentives for investigators might include
recruiting patients to a subsequent randomized study
phase. In addition, comedications to minimize the sever-
ity of adverse effects and time limited rescue strategies
for inefficacy that do not compromise the primary out-
come should also be considered. Another proposed pos-
sibility is the measurement of the “intent to attend” the
next study visit and to use this as a covariate to decrease
the attrition bias.
94 In addition, identifying patients who
are not likely to continue in the study or who find par-
ticipation burdensome prior to their dropping out can
help research personnel to proactively address barriers
to trial completion. Finally, allowing for in-person, two-
way video or telephone assessments in the patient’s
home should also be considered to reduce the amount
of missing data.
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One of the most neglected areas of clinical trials is trial
management and oversight. As signal detection has
become increasingly difficult and sample sizes have
increased, the conduct and quality control of large-scale
RCTs has become increasingly complex and difficult.
65
Subsequently, many companies have outsourced this
important aspect of trial implementation and perfor-
mance. As a result, there is the danger of a loss of con-
trol and diffusion or narrowing of responsibility, in that
clinical research organizations are mostly in charge of
assuring that increasingly tight time lines are kept and
quota are met. The enormous time pressures can lead to
a problematic disconnect between the desired quantity
and the desired quality of enrolled patients and assess-
ments. Moreover, increasing regulatory requirements
can also lead to an overburdening of sites and investi-
gators who are not part of professional clinical trials sites
and who might drop out of multisite RCTs, thereby nar-
rowing the settings in which patients are studied.
Furthermore, the focus on assuring adherence to formal
requirements, which has appropriately attracted scrutiny
and attention, should not distract from assessing the
quality of the trial conduct that is not equivalent to fol-
lowing checklists and increasingly complex documenta-
tion.
To overcome some of these problems, recent concern
has focused on finding ways to encourage trial manage-
ment organizations to broaden their responsibility
beyond considerations of documentation and fulfilling
quota. Rather, methods need to be considered that pro-
vide incentives to these organizations to assure adher-
ence to appropriate standards of patient selection and
high quality assessments, follow-up, protocol adherence,
and retention. However, a high placebo response or lack
of separation of the investigational drug or standard
comparator from placebo cannot automatically or solely
be used as a quality indicator. Moreover, quality adher-
ence should also be measurable and achievable during
the conduct of the trial and not only after its conclusion.
Therefore, the field needs to develop standards against
which sites and clinical trial management organizations
can be assessed and which can provide clear guidance to
all parties involved in the conduct of the trial.
Novel trial designs
In addition to addressing the issues and challenges pre-
viously discussed, there is also the need to explore novel
trial designs which can help to facilitate signal detection
and overall trial efficiency. There is a powerful clinical
tool that uses the patients’ own response pattern to pre-
dict outcomes. This intraindividual test of early
response/nonresponse as a predictor of subsequent
response
96,97 or the predictive value of dysphoric
response
98 had been studied briefly in the 1980s. As much
as 15 to 20 years later, these findings have been revisited
and expanded upon, stimulated by analyses showing
that, at least at a group level, the majority of antipsy-
chotic response occurs within the first few weeks
57,58 and,
even days
99 after antipsychotic initiation. Building on
these findings, a series of post-hoc analyses
59,60,100-102 plus a
recent prospective study
61 showed that nonresponse at
study end point can be predicted with high sensitivity,
specificity and predictive power by presence of less than
a minimal response, equivalent to less than 20% reduc-
tion in the Positive and Negative Syndrome Scale
103 or
Brief Psychiatric Rating Scale
104 total score at 2 weeks
after antipsychotic initiation. However, having identified
this general response pattern, questions remain as to
whether such trajectories are similar in the more likely
heterogeneous first-episode schizophrenia samples and
in treatment-refractory patients.
76,77 In addition, it needs
to be determined whether or not a limited set of specific
symptom items that could be used in clinical practice are
equally valid and reliable
105 and what one can learn from
symptom trajectories at an individual patient level.
106-109
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Figure 1. Novel drug development design utilizing early response/non-
response for sample enrichment. ↓, randomization time point
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This strategy would be very valuable in helping to deter-
mine what alternative treatments are likely to be more
successful after early nonresponse has been identified.
61
A novel design to help enhance signal-to-noise ratio in
an acute trial could take advantage of the response pat-
terns that have been identified (Figure 1). In the “early
responder randomized discontinuation design” all
patients are assigned to active drug, and then only those
who had at least a minimal response at 2 weeks are
enrolled in a double-blind, placebo-controlled discon-
tinuation trial. This design could potentially enrich the
placebo controlled portion of the trial with true drug
responders and thereby expose fewer patients to
placebo. A recent report by Marques et al
110 suggests that
those patients with a robust early response are less likely
to include placebo patients than other trajectories of
response. Appropriate data should be collected to deter-
mine what proportion of early responders would show
an exacerbation following placebo substitution and
within what time-frame. The ethical implications of such
a design should also be considered. Is an exacerbation
on placebo substitution for a subgroup of patients more
acceptable than a 4- to 6-week exposure to placebo for
a larger number of patients? At the same time, early
nonresponders at 2 weeks can also be used for reran-
domization to test strategies focusing on enhancing
response. In the mirror image “early nonresponder ran-
domized dose increase or augmentation design,” early
nonresponders at 2 weeks are assigned to staying on the
medication or going either to a higher dose or an aug-
mentation agent.The dose increase or augmentation
option will likely mostly be studied separately. However,
including both options in a three-arm design would also
be possible. This might be espcially attractive when
studying the addition of a second antipsychotic as the
augmentation strategy. Having the dose increase arm in
this design would allow distinguishing the effect of non-
dopaminergic receptor synergies vs mere increased
antipaminergic "dose" increase. 
In effect, this proposed design, “the early responder ran-
domized discontinuation design” is an alternative to a
previously proposed study design, “the sequential par-
allel comparison design.”
111 In contrast to the design that
we are proposing which has a 2-week active drug run-in
phase, the sequential parallel comparison study consists
of two phases of randomized treatment of equal dura-
tion. The first phase involves an unbalanced randomiza-
tion between placebo and active treatment with over-
sampling of placebo randomization. The second phase
involves re-randomization of placebo nonresponders to
active treatment or placebo. As patients in the second
phase “failed” placebo before, they are less likely to
respond to placebo, which diminishes the placebo
response and has the potential of enhancing power.
However, at the same time, drug response rates are also
likely to be reduced. The complication with this design
is the proposed data analytic technique that does not
only use patients from the second phase, ie, in an
enhanced sample of placebo nonresponders. Rather, out-
comes from both phases are combined in a complicated
pooling ratio.
111 However, were only patients from phase
two to be used, this would necessitate a very high num-
ber of patients to undergo the first phase. 
Conceivable alternatives to this design include two
phases of unequal duration with rerandomization of
early placebo nonresponders (in schizophrenia: <20%
reduction in PANSS total score) after only 2 weeks to
either placebo or active treatment (ie, early placebo non-
responder sequential parallel comparison design).
Alternatively, a triple-blind, 2-week placebo lead-in
phase could precede randomization to drug or placebo
in patients with <20% reduction in PANSS total score,
rather than randomizing patients without a "full"
response (however defined in a given study and disease)
at 4 weeks or longer, as proposed in the sequential par-
allel comparison design.
As can be seen from these examples, the enrichment
strategy of focusing on early responders or nonrespon-
ders to either drug or placebo could potentially be lever-
aged to enhance the signal-to-noise ratio, depending on
the question that is being asked.
Summary and conclusions
Clinical trials, like everything else man-made, are
imperfect. Their specific content and success are con-
text dependent. A number of factors that were outlined
in this article need to be considered, controlled, moni-
tored, and improved upon. In addition to a number of
standard features, the design of RCTs needs to be tai-
lored to the research question, population, illness
phase, setting, active treatment, control condition and
outcome under investigation. Patient selection, blind-
ing, ratings, study/site management and adherence are
important aspects. Innovative designs should be con-
sidered in order to deal with some of the inevitable
PAGES_12_AG_1003_BA.qxd:DCNS#49  31/05/11  0:16  Page 167State of the art
168
compromises involved in designing and conducting
RCTs. For some research questions, alternative study
types might need to be considered, such as cohort,
pharmacoepidemiologic database or registry studies.
Importantly, measurable quality standards for RCTs
need to be developed. Applying these standards along
with novel ways to incentivize all of the parties
involved in order to achieve increased adherence to
quality measures need to be explored. To achieve this,
the different stakeholders should share experiences
and actual data to come up with appropriate solutions.
We need to learn from the past as much as possible and
we need to appreciate that failed and uninformative tri-
als, increasing placebo response rates and increased
sample size requirements in the context of decreasing
effect sizes are a critical and destructive, but shared
problem that needs viable solutions. Without this
shared responsibility for the design and conduct of high
quality trials, the development of new compounds and
the broadening of indications for patients in strong
need of effective and safe treatment alternatives will
become increasingly difficult. In addition, more and
more companies will be discouraged from pursuing
these therapeutic targets for drug development. Finally,
the utility of novel trial designs that decrease placebo
response and enrich samples should be tested and their
appropriateness for regulatory approval pathways
needs to be explored. ❏
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Ensayos controlados randomizados en esquizofrenia: oportunidades, limitaciones y 
alternativas de diseño de ensayos
El estado del arte en el diseño y la metodología de los ensayos clínicos es de gran importancia para el avance
en este campo. A la inversa, la importancia crítica del manejo e implementación del ensayo sólo ha sido
recientemente el foco de discusión e investigación. Aunque los ensayos controlados randomizados son con-
siderados generalmente el gold standard para la evaluación de las intervenciones farmacológicas y no far-
macológicas en medicina, los ensayos son sensibles a las complicaciones e influencias que pueden compro-
meter seriamente su éxito. Al igual que las intervenciones, el diseño y manejo de los ensayos también
dependen del contexto. Ellos necesitan estar individualizados y adaptados a un número de variables rele-
vantes, tales como el lugar, la población, la fase de la enfermedad, las intervenciones, las expectativas y ses-
gos del paciente y del evaluador, y los objetivos generales de la investigación. Dado que no existe un enfo-
que uniforme factible, se deben considerar cuidadosamente ciertos principios y guías generales. El
conocimiento de soluciones y alternativas básicas, y el reconocimiento de los complejos desafíos que nece-
sitan emprenderse proactivamente pueden ayudar a minimizar los resultados no deseados, incluyendo la
falla del ensayo y los resultados mal informados o falsos negativos. Sin embargo, las alternativas de un
nuevo diseño necesitan ser exploradas con el aporte de una muestra objetivo de acuerdo a la pregunta del
estudio y con un aumento de la precisión en la medición de resultados relevantes.  Se proponen dos estra-
tegias de un  nuevo diseño que aprovechan el paradigma de respuesta de antipsicóticos recientemente vali-
dado (que también se ha aplicado a antidepresivos y estabilizadores del ánimo). En el “diseño de disconti-
nuación randomizado del respondedor precoz” todos los pacientes son asignados al fármaco activo, y sólo
los que tienen al menos una mínima respuesta a las dos semanas se incorporan a un ensayo de disconti-
nuación doble-ciego, placebo-controlado, con lo que aumenta la porción del ensayo controlada por  pla-
cebo con los verdaderos respondedores al fármaco. En la imagen especular  del “diseño de aumentación o
aumento randomizado de dosis de los no respondedores precoces”, los no respondedores precoces a las
dos semanas son asignados a mantener la medicación o bien a una dosis mayor o a un agente potenciador.
Es de esperar que mediante una mayor atención a los temas planteados en este artículo y a un mayor refi-
namiento en la metodología y el manejo de los ensayos, esta área aporte progresos adicionales en la pre-
vención y tratamiento de la esquizofrenia.
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Études contrôlées randomisées dans la schizophrénie : opportunités, limites et schémas 
d’étude alternatifs
La méthodologie et le schéma des études cliniques les plus récentes sont extrêmement importants pour les
progrès dans ce domaine. À l’inverse, la pertinence de la mise en œuvre et du déroulement de l’étude n’a
été que plus récemment le centre des discussions et des recherches. Bien que les études contrôlées rando-
misées soient généralement considérées comme la méthode de référence pour l’évaluation des traitements
pharmacologiques et non pharmacologiques en médecine, elles sont soumises à des complications et à des
biais qui peuvent gravement compromettre leur succès. Comme toute intervention, la conduite et le schéma
des études, dépendent du contexte. Ils doivent être individualisés et adaptés à un certain nombre de varia-
bles pertinentes, comme l’environnement, la population, la phase de la maladie, les traitements, les biais
et les attentes des patients et des évaluateurs ainsi que les objectifs globaux de la recherche. Même si une
approche unifiée est impossible, certains principes et recommandations généraux demandent un examen
attentif. La connaissance des solutions de base et de leurs alternatives, et celle des défis complexes néces-
sitant d’être pris en charge préventivement, peuvent aider à minimiser des résultats non désirés, comme
l’échec de l’étude et l’obtention de résultats sans intérêts ou faussement négatifs. De plus, il faut étudier
de nouvelles alternatives de schémas d’études afin d’enrichir les échantillons en fonction des questions de
l’étude et améliorer la précision de mesure de résultats pertinents. Nous proposons deux nouvelles stra-
tégies de schémas d’études qui profitent du modèle de réponse antipsychotique précoce récemment validé
(qui a aussi été observé avec des antidépresseurs et des régulateurs de l’humeur). Dans le schéma de 
« répondeurs précoces randomisés pour l’arrêt de traitement » tous les patients reçoivent un médicament
actif, et seuls ceux qui avaient au moins une réponse minimale à 2 semaines sont inclus pour une étude
d’interruption en double aveugle, contrôlée contre placebo, ce qui permet d’enrichir la partie de l’étude
contrôlée contre placebo avec de vrais répondeurs au traitement. À l’inverse,« les non-répondeurs préco-
ces randomisés pour escalade de dose ou coprescription», doivent à 2 semaines continuer leur traitement
et soit augmenter leur dose soit bénéficier d’une prescription complémentaire. Nous espérons que grâce à
l’intérêt accru pour les problèmes soulevés dans cet article et à la précision plus rigoureuse dans le dérou-
lement et la méthodologie des études, des progrès supplémentaires bien nécessaires verront le jour dans
le domaine, pour la prévention et le traitement de la schizophrénie.
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